Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant.

Nitric oxide (NO) is known to play a role in the non-specific host defence mechanism. Furthermore, it has been proposed that NO may be important in respiratory defence against the viruses which cause the common cold. Indeed, elevated NO levels have previously been observed in orally expired air during upper respiratory tract infection (URTI). We wanted to investigate further the role of NO in the host response to URTI. Total nasal airway resistance (tNAR) and nasal NO levels were obtained during symptomatic URTI in 97 subjects. Of these, 80 received treatment with either oxymetazoline or a placebo spray. Post-treatment tNAR and NO levels were obtained 60 min after treatment. Measurements of NO were also repeated 4-6 weeks later, when subjects were healthy, (n = 82). NO levels were measured using a chemiluminescence gas analyse whilst tNAR was measured using posterior rhinomanometry. The mean pre-treatment NO level (1063 +/- 541 ppb) was shown to be reduced significantly after treatment with oxymetazoline (827 +/- 373ppb), p < 0.0001. The mean pre-treatment tNAR, 0.42 Pa cm-3 sec-1, was also reduced significantly to 0.21 Pa cm-1 sec-1 (p < 0.001) after treatment with oxymetazoline. There was no significant correlation between the change in NO levels and change in tNAR following treatment with oxymetazoline (p. corrected for ties = 0.011, p = 0.98. No significant difference was found between NO levels obtained during URTI (1130 +/- 444 ppb) when compared to values obtained when healthy (1197 +/- 361 ppb), p = 0.25. These results demonstrate that treatment with a topical nasal decongestant spray causes a reduction in nasal NO levels. We propose that this occurs as an indirect consequence of the vasoconstrictor actions of oxymetazoline. Since no change in NO levels was observed during URTI, we propose that the NO synthase responsible for NO production in the nose responds in a different manner to that in the lungs.

[1]  K. Croen,et al.  Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. , 1993, The Journal of clinical investigation.

[2]  E. Weitzberg,et al.  Primarily nasal origin of exhaled nitric oxide and absence in Kartagener's syndrome. , 1994, The European respiratory journal.

[3]  J. Rinder.  Sensory neuropeptides and nitric oxide in nasal vascular regulation. , 1996, Acta physiologica Scandinavica. Supplementum.

[4]  F. Chagnon,et al.  Expression of nitric oxide synthase in the human nasal mucosa. , 1996, American journal of respiratory and critical care medicine.

[5]  D. Yates,et al.  Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. , 1995, The European respiratory journal.

[6]  T. Hökfelt,et al.  High nitric oxide production in human paranasal sinuses , 1995, Nature Medicine.

[7]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[8]  P. Vallance,et al.  Fortnightly Review Biology and clinical relevance of nitric oxide , 1994, BMJ.

[9]  L. Gustafsson,et al.  Contribution from upper and lower airways to exhaled endogenous nitric oxide in humans , 1995, Acta anaesthesiologica Scandinavica.

[10]  M. Bende,et al.  Vascular effects of topical oxymetazoline on human nasal mucosa , 1986, The Journal of Laryngology & Otology.

[11]  N. Zamel,et al.  Acoustic rhinometry in the evaluation of nasal obstruction , 1995, The Laryngoscope.

[12]  G. Karupiah,et al.  Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. , 1993, Science.

[13]  J. Lundberg.  Airborne nitric oxide: Inflammatory marker and aerocrine messenger in man. , 1996, Acta physiologica Scandinavica.